ONCR - Oncorus, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
ONCR price evolution
ONCR
| (in millions $) | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $24.65 | $29.15 | $45.01 | $88.23 |
| Short term investments | $23.77 | $36.49 | $39.95 | $15.44 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $46.67 | $64.62 | $83.48 | $102.76 |
| Long term investments | ||||
| Property, plant & equipment | $59.07 | $76.92 | $76.88 | $75.39 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $63.08 | $80.97 | $80.89 | $79.78 |
| Total investments | $23.77 | $36.49 | $39.95 | $15.44 |
| Total assets | $109.75 | $145.59 | $164.37 | $182.54 |
| Current liabilities | ||||
| Accounts payable | $2.76 | $5.69 | $1.98 | $7.16 |
| Deferred revenue | ||||
| Short long term debt | $20.54 | $19.44 | ||
| Total current liabilities | $31.11 | $37.21 | $16.81 | $16.02 |
| Long term debt | $47.52 | $47.85 | $67.4 | $68.35 |
| Total noncurrent liabilities | $47.52 | $47.85 | $67.56 | $68.52 |
| Total debt | $68.06 | $67.29 | $67.4 | $68.35 |
| Total liabilities | $78.63 | $85.06 | $84.37 | $84.53 |
| Shareholders' equity | ||||
| Retained earnings | -$302.91 | -$272.01 | -$251.08 | -$231.46 |
| Other shareholder equity | -$0.02 | -$0.05 | -$0.07 | -$0.04 |
| Total shareholder equity | $31.12 | $60.52 | $80 | $98.01 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $29.15 | $104.19 | $133.18 | $45.29 |
| Short term investments | $36.49 | $23.17 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $64.62 | $129.11 | $133.39 | $45.9 |
| Long term investments | ||||
| Property, plant & equipment | $76.92 | $68.45 | $45.55 | $4.47 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $80.97 | $72.48 | $48.87 | $4.92 |
| Total investments | $36.49 | $23.17 | ||
| Total assets | $145.59 | $201.59 | $182.26 | $50.83 |
| Current liabilities | ||||
| Accounts payable | $5.69 | $13.01 | $1.25 | $0.94 |
| Deferred revenue | $0.47 | |||
| Short long term debt | $19.44 | |||
| Total current liabilities | $37.21 | $20.97 | $5.98 | $4.94 |
| Long term debt | $47.85 | $50.39 | $41.62 | |
| Total noncurrent liabilities | $47.85 | $50.59 | $41.62 | $3.55 |
| Total debt | $67.29 | $50.39 | $41.62 | |
| Total liabilities | $85.06 | $71.56 | $47.6 | $8.49 |
| Shareholders' equity | ||||
| Retained earnings | -$272.01 | -$194.59 | -$129.82 | -$74.3 |
| Other shareholder equity | -$0.05 | -$0.01 | ||
| Total shareholder equity | $60.52 | $130.02 | $134.66 | -$74.3 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $10.63 | $15.71 | $14.09 | $12.48 |
| Selling, general & administrative | $4.5 | $5.07 | $5.21 | $6.16 |
| Total operating expenses | $29.7 | $20.78 | $19.3 | $18.64 |
| Operating income | -$29.7 | -$20.78 | -$19.3 | -$18.64 |
| Income from continuing operations | ||||
| EBIT | -$29.7 | -$20.51 | -$19.29 | -$18.67 |
| Income tax expense | ||||
| Interest expense | $1.2 | $0.42 | $0.33 | $0.42 |
| Net income | ||||
| Net income | -$30.9 | -$20.93 | -$19.62 | -$19.09 |
| Income (for common shares) | -$30.9 | -$20.93 | -$19.62 | -$19.09 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $54.74 | $44.68 | $27.15 | $24.05 |
| Selling, general & administrative | $21.79 | $20.14 | $10 | $7.12 |
| Total operating expenses | $76.54 | $64.82 | $37.15 | $31.17 |
| Operating income | -$76.54 | -$64.82 | -$37.15 | -$31.17 |
| Income from continuing operations | ||||
| EBIT | -$76.33 | -$64.76 | -$48.3 | -$30.7 |
| Income tax expense | ||||
| Interest expense | $1.09 | |||
| Net income | ||||
| Net income | -$77.42 | -$64.76 | -$48.3 | -$30.7 |
| Income (for common shares) | -$77.42 | -$64.76 | -$56.83 | -$34.99 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$30.9 | -$20.93 | -$19.62 | -$19.09 |
| Operating activities | ||||
| Depreciation | $1.1 | $1.64 | $0.85 | $0.56 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.47 | $1.41 | $1.64 | $2.18 |
| Total cash flows from operations | -$17.45 | -$14.14 | -$10.85 | -$13.26 |
| Investing activities | ||||
| Capital expenditures | -$0.07 | -$5.45 | -$7.92 | -$4.69 |
| Investments | $13.03 | $3.7 | -$24.45 | $7.68 |
| Total cash flows from investing | $12.96 | -$1.75 | -$32.38 | $2.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.1 | ||
| Net borrowings | $19.47 | |||
| Total cash flows from financing | $0.03 | $19.56 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4.49 | -$15.86 | -$43.23 | $9.29 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$77.42 | -$64.76 | -$48.3 | -$30.7 |
| Operating activities | ||||
| Depreciation | $3.63 | $1.95 | $1.37 | $1.07 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.21 | $6.57 | $1.74 | $0.71 |
| Total cash flows from operations | -$61.69 | -$49.82 | -$36.81 | -$27.2 |
| Investing activities | ||||
| Capital expenditures | -$19.93 | -$9.55 | -$1.06 | -$0.98 |
| Investments | -$13.07 | -$23.18 | ||
| Total cash flows from investing | -$33.01 | -$32.73 | -$1.06 | -$0.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.19 | $53.56 | $89.94 | $0.06 |
| Net borrowings | $19.47 | |||
| Total cash flows from financing | $19.65 | $53.56 | $125.76 | $53.39 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$75.04 | -$28.99 | $87.9 | $25.21 |
News
Fundamentals
| Market cap | $675.86K |
|---|---|
| Enterprise value | $44.08M |
| Shares outstanding | 26.09M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$84.03M |
| EBIT | -$88.17M |
| Net Income | -$90.54M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.01 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.52 |
| EV/EBIT | -0.50 |
| P/S ratio | N/A |
| P/B ratio | 0.02 |
| Book/Share | 1.19 |
| Cash/Share | 0.94 |
| EPS | -$3.47 |
|---|---|
| ROA | -60.14% |
| ROE | -134.31% |
| Debt/Equity | 1.41 |
|---|---|
| Net debt/EBITDA | -0.64 |
| Current ratio | 1.50 |
| Quick ratio | 1.50 |